- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07655206
Home-based Exercise Therapy in Patients With Moderate to Severe Peripheral Artery Disease (PILOT-PADCYCLE)
Effectiveness of a Home-based Cardiovascular Rehabilitation Program Compared With Standard Care in Patients With Moderate to Severe Peripheral Artery Disease: a Pilot Randomized Controlled Trial (PILOT-PAD-CYCLE)
Peripheral arterial disease (PAD) is a chronic atherosclerotic condition associated with impaired mobility, reduced quality of life, cardiovascular events, and risk of lower limb amputation. Although supervised exercise therapy (SET) is recommended for symptomatic PAD, access and adherence remain limited, particularly among patients with moderate-to-severe disease or chronic limb-threatening ischemia (CLTI).
The PILOT-PAD-CYCLE study is a prospective, single-center, pilot randomized controlled trial designed to evaluate the feasibility, acceptability, and preliminary efficacy of a 12-week home-based exercise therapy (HET) program using a portable pedal exerciser in adults with moderate-to-severe PAD, including CLTI, with or without foot wounds.
Twelve participants will be randomized 1:1 to either HET plus standard care or standard care alone. The intervention includes individualized exercise prescription, remote supervision by a kinesiologist, cardiovascular education, and follow-up over 12 weeks. Outcomes include feasibility and acceptability metrics, 6-minute walk test distance, vascular perfusion indices, quality of life, and cardiovascular events up to 6 months.
This pilot trial aims to generate feasibility data and preliminary efficacy estimates to support the development of a future multicenter randomized controlled trial.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Peripheral arterial disease (PAD) is a major manifestation of systemic atherosclerosis and is associated with impaired walking capacity, functional decline, cardiovascular morbidity, reduced quality of life, and increased risk of lower limb amputation. Patients with moderate-to-severe PAD and chronic limb-threatening ischemia (CLTI) represent a particularly vulnerable population with substantial mobility limitations and high rates of cardiovascular events and mortality.
Supervised exercise therapy (SET) is recommended as a first-line therapy for symptomatic PAD and has demonstrated significant benefits on walking performance, functional capacity, and quality of life. However, access to SET programs remains limited in many regions due to geographic barriers, transportation difficulties, costs, limited specialized infrastructure, and poor adherence, particularly among individuals with advanced PAD, foot wounds, frailty, or mobility impairment.
Home-based exercise therapy (HET) has emerged as a promising alternative to traditional SET. Portable pedal exercisers may provide a low-cost, accessible, and feasible exercise modality for patients unable to participate in treadmill-based rehabilitation programs. However, evidence regarding the feasibility, acceptability, and preliminary efficacy of pedal exerciser-based HET in patients with moderate-to-severe PAD or CLTI remains limited.
The PILOT-PAD-CYCLE study is a prospective, single-center, pilot randomized controlled trial conducted at Hôtel-Dieu de Lévis (Québec, Canada). The study aims to evaluate the feasibility and acceptability of a 12-week HET program using a portable pedal exerciser in adults with moderate-to-severe PAD, including patients with foot wounds.
Twelve participants will be randomized in a 1:1 ratio to either:
- HET combined with standard vascular care; or
- Standard vascular care alone.
The intervention group will receive an individualized home-based exercise prescription supervised remotely by a kinesiologist. Participants will be encouraged to perform structured exercise sessions using a portable pedal exerciser over a 12-week period. The intervention also includes cardiovascular risk factor education, exercise progression monitoring, and regular follow-up contacts to support adherence and safety.
Feasibility outcomes include recruitment rate, retention rate, intervention adherence, completion of study assessments, and adverse events. Acceptability will be evaluated through participant satisfaction and perceived usability of the intervention.
Preliminary efficacy outcomes include changes in walking capacity measured by the 6-minute walk test, vascular perfusion parameters, patient-reported quality of life, pain, wound-related outcomes when applicable, and cardiovascular or limb-related events during follow-up up to 6 months.
This pilot trial is intended to provide essential feasibility data, estimate variability of clinical outcomes, and inform the design and sample size calculation of a future multicenter randomized controlled trial evaluating home-based pedal exerciser rehabilitation in patients with moderate-to-severe PAD and foot wounds.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Jérôme Patry, DPM, MD, MSc
- Telefonnummer: 11393 418-835-7121
- E-Mail: jerome.patry.1@ulaval.ca
Studienorte
-
-
Quebec
-
Lévis, Quebec, Kanada, G6V 3Z1
- Hôtel-Dieu de Lévis, CISSS de Chaudière-Appalaches
-
Kontakt:
- Jérôme Patry, DPM, MD, MSc
- Telefonnummer: 11393 418-835-7121
- E-Mail: jerome.patry.1@ulaval.ca
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Adults aged 18 years or older
- Moderate-to-severe peripheral arterial disease defined by at least one of the following:
ABI < 0.6 Ankle systolic pressure < 70 mmHg Toe systolic pressure < 40 mmHg Toe-brachial index < 0.4
- With or without lower limb wound
- Declined referral to an in-person supervised exercise therapy program
- Able to provide informed consent
Exclusion Criteria:
- Lower limb revascularization within the previous 30 days
- Planned revascularization during the first 12 weeks of the study
- Unable to use a portable pedal exerciser
- Unable to perform a 6-minute walk test
- Medically unstable according to the treating clinical or rehabilitation team
- Participation in a cardiovascular rehabilitation program within the previous year
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Home-based exercise therapy (HET) plus standard care
Standard care
|
Participants randomized to the intervention arm will receive a 12-week individualized home-based cardiovascular rehabilitation program using a portable pedal exerciser. The intervention includes: Initial 60-minute educational session Aerobic exercise prescription (3-5 sessions/week; 10-30 minutes/session) Moderate exercise intensity (Borg 3-5/10) Resistance exercises 2-3 times/week Telephone or videoconference follow-up twice weekly Cardiovascular risk factor counseling and educational support Walking exercise may also be prescribed when clinically appropriate. |
|
Kein Eingriff: Standard Care
Usual standard care delivered by their physician for peripheral artery disease
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Feasibility of the HET Program
Zeitfenster: Baseline and 13 weeks
|
Assessment of recruitment rate, adherence to prescribed exercise sessions, intervention completion (in %)
|
Baseline and 13 weeks
|
|
Acceptability of the HET program : questionnaire
Zeitfenster: 13 weeks
|
Participants acceptability questionnaire score (numeric score from 4 to 20; 4 representing the lowest acceptability score and 20 representing the highest acceptability score)
|
13 weeks
|
|
Acceptability of HET program : qualitative interview findings
Zeitfenster: Between 13 weeks and 25 weeks
|
Participants acceptability based on a semi-structured interview (no units of measure)
|
Between 13 weeks and 25 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in 6-Minute Walk Test Distance
Zeitfenster: Baseline and 13 weeks
|
Difference in walking distance measured during the 6-minute walk test between baseline and week 13.
(in meters)
|
Baseline and 13 weeks
|
|
Change in peripheral vascular perfusion : ankle-brachial index (ABI)
Zeitfenster: Baseline and 13 weeks
|
Difference in ankle-brachial index (ABI) between baseline and week 13 (no units of measure)
|
Baseline and 13 weeks
|
|
Change in peripheral vascular perfusion : toe-brachial index (TBI)
Zeitfenster: Baseline and 13 weeks
|
Difference in toe-brachial index values between baseline and week 13 (no units of measure)
|
Baseline and 13 weeks
|
|
Change in peripheral vascular perfusion : toe systolic pressure measurements
Zeitfenster: Baseline and 13 weeks
|
Difference in toe systolic pressure measurements between baseline and week 13 (mmHg)
|
Baseline and 13 weeks
|
|
Change in Quality of Life
Zeitfenster: Baseline and 13 weeks
|
Changes in quality of life measured using the SF-36 questionnaire.
|
Baseline and 13 weeks
|
|
Major Cardiovascular Events
Zeitfenster: Up to 6 months after completion of the intervention
|
Occurrence of any major cardiovascular events (including revascularization, amputation, myocardial infarction, stroke, chronic limb-threatening ischemia progression, and death)
|
Up to 6 months after completion of the intervention
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, Gardner AW, Hiatt WR, Regensteiner JG, Rich K; American Heart Association Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Council on Cardiovascular and Stroke Nursing. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019 Jan 22;139(4):e10-e33. doi: 10.1161/CIR.0000000000000623. No abstract available.
- Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, Bura-Riviere A, De Backer J, Deglise S, Della Corte A, Heiss C, Kaluzna-Oleksy M, Kurpas D, McEniery CM, Mirault T, Pasquet AA, Pitcher A, Schaubroeck HAI, Schlager O, Sirnes PA, Sprynger MG, Stabile E, Steinbach F, Thielmann M, van Kimmenade RRJ, Venermo M, Rodriguez-Palomares JF; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Sep 29;45(36):3538-3700. doi: 10.1093/eurheartj/ehae179. No abstract available.
- Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, Chandra V, Drachman DE, Eaves JM, Ehrman JK, Evans JN, Getchius TSD, Gutierrez JA, Hawkins BM, Hess CN, Ho KJ, Jones WS, Kim ESH, Kinlay S, Kirksey L, Kohlman-Trigoboff D, Long CA, Pollak AW, Sabri SS, Sadwin LB, Secemsky EA, Serhal M, Shishehbor MH, Treat-Jacobson D, Wilkins LR; Peer Review Committee Members. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jun 11;149(24):e1313-e1410. doi: 10.1161/CIR.0000000000001251. Epub 2024 May 14.
- Harwood AE, Smith GE, Cayton T, Broadbent E, Chetter IC. A Systematic Review of the Uptake and Adherence Rates to Supervised Exercise Programs in Patients with Intermittent Claudication. Ann Vasc Surg. 2016 Jul;34:280-9. doi: 10.1016/j.avsg.2016.02.009. Epub 2016 Apr 25.
- Thomas RJ, Beatty AL, Beckie TM, Brewer LC, Brown TM, Forman DE, Franklin BA, Keteyian SJ, Kitzman DW, Regensteiner JG, Sanderson BK, Whooley MA. Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. J Am Coll Cardiol. 2019 Jul 9;74(1):133-153. doi: 10.1016/j.jacc.2019.03.008. Epub 2019 May 13.
- Ahiskali GN, Demirel A, Yamikan H, Kutukcu EC. The effects of upper extremity and lower extremity aerobic exercise training in patients with peripheral arterial disease: A systematic review. J Vasc Surg. 2026 Jan;83(1):305-316.e2. doi: 10.1016/j.jvs.2025.07.060. Epub 2025 Aug 23.
- Patry J, Hebert AA, Ross MK. Should We Prescribe a Pedal Exerciser for Every Patient With Peripheral Artery Disease? A Low-Cost Tool Against High-Stakes Complications. Can J Cardiol. 2025 Dec;41(12):2627-2628. doi: 10.1016/j.cjca.2025.09.003. Epub 2025 Sep 9. No abstract available.
- Iso Y, Suzuki H, Kyuno E, Maeda A, Tsunoda F, Miyazawa R, Kowaita H, Kitai H, Takahashi T, Sambe T. Therapeutic potential of cycling high-intensity interval training in patients with peripheral artery disease: A pilot study. Int J Cardiol Heart Vasc. 2018 Feb 21;18:30-32. doi: 10.1016/j.ijcha.2018.02.002. eCollection 2018 Mar. No abstract available.
- Cetlin MD, Polonsky T, Ho K, Zhang D, Tian L, Zhao L, Greenland P, Treat-Jacobson D, Kibbe MR, Criqui MH, Guralnik JM, McDermott MM. Barriers to participation in supervised exercise therapy reported by people with peripheral artery disease. J Vasc Surg. 2023 Feb;77(2):506-514. doi: 10.1016/j.jvs.2022.09.014. Epub 2022 Sep 20.
- Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH; GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019 Jun;69(6S):3S-125S.e40. doi: 10.1016/j.jvs.2019.02.016. Epub 2019 May 28.
- Mazzolai L, Belch J, Venermo M, Aboyans V, Brodmann M, Bura-Riviere A, Debus S, Espinola-Klein C, Harwood AE, Hawley JA, Lanzi S, Madaric J, Mahe G, Malatesta D, Schlager O, Schmidt-Trucksass A, Seenan C, Sillesen H, Tew GA, Visona A. Exercise Therapy for Chronic Symptomatic Peripheral Artery Disease: A Clinical Consensus Document of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases in Collaboration With the European Society of Vascular Medicine and the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg. 2024 Feb 16:S1078-5884(24)00011-X. doi: 10.1016/j.ejvs.2024.01.009. Online ahead of print.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Chronische Erkrankung
- Krankheitsattribute
- Atherosklerose
- Arteriosklerose
- Arterielle Verschlusskrankheiten
- Ischämie
- Pathologische Zustände, Anzeichen und Symptome
- Chronische, die Gliedmaßen bedrohende Ischämie
- Periphere arterielle Verschlusskrankheit
- Periphere Gefäßerkrankungen
Andere Studien-ID-Nummern
- CISSSCA-2026-1325
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Periphere arterielle Verschlusskrankheit
-
Zhejiang Cancer HospitalRekrutierungHepatic Artery Infusion | Lebermetastasen bei BrustkrebsChina